Literature DB >> 21148502

Different innate signatures induced in human monocyte-derived dendritic cells by wild-type dengue 3 virus, attenuated but reactogenic dengue 3 vaccine virus, or attenuated nonreactogenic dengue 1-4 vaccine virus strains.

Claire Balas1, Audrey Kennel, Florence Deauvieau, Regis Sodoyer, Nadege Arnaud-Barbe, Jean Lang, Bruno Guy.   

Abstract

DNA microarrays were used to assess the innate gene signature in human myeloid dendritic cells infected with chimeric dengue 1-4 vaccines, a wild-type dengue 3 virus, or a classically attenuated serotype 3 vaccine shown to be reactogenic in humans. We observed a very reproducible signature for each of the 4 chimeric dengue vaccines, involving stimulation of type I interferon and associated genes, together with genes encoding chemokines and other mediators involved in the initiation of adaptive responses. In contrast, wild-typeDEN3 virus induced a predominantly inflammatory profile, while the reactogenic attenuated serotype 3 vaccine appeared to induce a blunted response.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21148502      PMCID: PMC3086443          DOI: 10.1093/infdis/jiq022

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  15 in total

1.  Addition of interferon-alpha to a standard maturation cocktail induces CD38 up-regulation and increases dendritic cell function.

Authors:  Redas Trepiakas; Anders Elm Pedersen; Ozcan Met; Inge Marie Svane
Journal:  Vaccine       Date:  2009-02-13       Impact factor: 3.641

2.  Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis.

Authors:  D H Libraty; S Pichyangkul; C Ajariyakhajorn; T P Endy; F A Ennis
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.

Authors:  Dennis Morrison; Thomas J Legg; Christopher W Billings; Remi Forrat; Sutee Yoksan; Jean Lang
Journal:  J Infect Dis       Date:  2010-02-01       Impact factor: 5.226

4.  TRAIL is a novel antiviral protein against dengue virus.

Authors:  Rajas V Warke; Katherine J Martin; Kris Giaya; Sunil K Shaw; Alan L Rothman; Irene Bosch
Journal:  J Virol       Date:  2007-10-03       Impact factor: 5.103

5.  Patterns of gene transcript abundance in the blood of children with severe or uncomplicated dengue highlight differences in disease evolution and host response to dengue virus infection.

Authors:  Hoang Truong Long; Martin L Hibberd; Tran Tinh Hien; Nguyen Minh Dung; Tran Van Ngoc; Jeremy Farrar; Bridget Wills; Cameron P Simmons
Journal:  J Infect Dis       Date:  2009-02-15       Impact factor: 5.226

Review 6.  Preclinical and clinical development of YFV 17D-based chimeric vaccines against dengue, West Nile and Japanese encephalitis viruses.

Authors:  Bruno Guy; Farshad Guirakhoo; Veronique Barban; Stephen Higgs; Thomas P Monath; Jean Lang
Journal:  Vaccine       Date:  2009-10-04       Impact factor: 3.641

7.  Transcriptional activation of interferon-stimulated genes but not of cytokine genes after primary infection of rhesus macaques with dengue virus type 1.

Authors:  Carlos A Sariol; Jorge L Muñoz-Jordán; Kristina Abel; Lymarie C Rosado; Petraleigh Pantoja; Luis Giavedoni; Idia Vanessa Rodriguez; Laura J White; Melween Martínez; Teresa Arana; Edmundo N Kraiselburd
Journal:  Clin Vaccine Immunol       Date:  2007-04-11

8.  Gene expression profiling of dengue infected human primary cells identifies secreted mediators in vivo.

Authors:  Aniuska Becerra; Rajas V Warke; Katherine Martin; Kris Xhaja; Norma de Bosch; Alan L Rothman; Irene Bosch
Journal:  J Med Virol       Date:  2009-08       Impact factor: 2.327

9.  Dengue virus regulates type I interferon signalling in a strain-dependent manner in human cell lines.

Authors:  Indira Umareddy; Kin Fai Tang; Subhash G Vasudevan; Shamala Devi; Martin L Hibberd; Feng Gu
Journal:  J Gen Virol       Date:  2008-12       Impact factor: 3.891

10.  Regulation of leukocyte recruitment by the long pentraxin PTX3.

Authors:  Livija Deban; Remo Castro Russo; Marina Sironi; Federica Moalli; Margherita Scanziani; Vanessa Zambelli; Ivan Cuccovillo; Antonio Bastone; Marco Gobbi; Sonia Valentino; Andrea Doni; Cecilia Garlanda; Silvio Danese; Giovanni Salvatori; Marica Sassano; Virgilio Evangelista; Barbara Rossi; Elena Zenaro; Gabriela Constantin; Carlo Laudanna; Barbara Bottazzi; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-03-07       Impact factor: 25.606

View more
  15 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine.

Authors:  Bruno Guy
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 2.  Latest developments and future directions in dengue vaccines.

Authors:  Usa Thisyakorn; Chule Thisyakorn
Journal:  Ther Adv Vaccines       Date:  2014-01

3.  Dengue virus type 3 isolated from a fatal case with visceral complications induces enhanced proinflammatory responses and apoptosis of human dendritic cells.

Authors:  Guilherme F Silveira; Florencia Meyer; Adriana Delfraro; Ana Luiza P Mosimann; Norma Coluchi; Cyntia Vasquez; Christian M Probst; André Báfica; Juliano Bordignon; Claudia N Duarte Dos Santos
Journal:  J Virol       Date:  2011-03-30       Impact factor: 5.103

Review 4.  Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.

Authors:  Bruno Guy; Nicholas Jackson
Journal:  Nat Rev Microbiol       Date:  2015-12-07       Impact factor: 60.633

5.  Immunosignatures can predict vaccine efficacy.

Authors:  Joseph Barten Legutki; Stephen Albert Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-28       Impact factor: 11.205

6.  Genome-wide host responses against infectious laryngotracheitis virus vaccine infection in chicken embryo lung cells.

Authors:  Jeongyoon Lee; Walter G Bottje; Byung-Whi Kong
Journal:  BMC Genomics       Date:  2012-04-24       Impact factor: 3.969

Review 7.  Strategic applications of gene expression: from drug discovery/development to bedside.

Authors:  Jane P F Bai; Alexander V Alekseyenko; Alexander Statnikov; I-Ming Wang; Peggy H Wong
Journal:  AAPS J       Date:  2013-01-15       Impact factor: 3.603

8.  High-throughput quantitative proteomic analysis of dengue virus type 2 infected A549 cells.

Authors:  Han-Chen Chiu; Holger Hannemann; Kate J Heesom; David A Matthews; Andrew D Davidson
Journal:  PLoS One       Date:  2014-03-26       Impact factor: 3.240

9.  Host cell transcriptome profile during wild-type and attenuated dengue virus infection.

Authors:  October M Sessions; Ying Tan; Kenneth C Goh; Yujing Liu; Patrick Tan; Steve Rozen; Eng Eong Ooi
Journal:  PLoS Negl Trop Dis       Date:  2013-03-14

10.  Molecular determinants of plaque size as an indicator of dengue virus attenuation.

Authors:  Kenneth Choon Meng Goh; Choon Kit Tang; Diana Catherine Norton; Esther Shuyi Gan; Hwee Cheng Tan; Bo Sun; Ayesa Syenina; Amjad Yousuf; Xin Mei Ong; Uma Sangumathi Kamaraj; Yin Bun Cheung; Duane J Gubler; Andrew Davidson; Ashley Lauren St John; October Michael Sessions; Eng Eong Ooi
Journal:  Sci Rep       Date:  2016-05-17       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.